[go: up one dir, main page]

DE60037327D1 - Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften - Google Patents

Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften

Info

Publication number
DE60037327D1
DE60037327D1 DE60037327T DE60037327T DE60037327D1 DE 60037327 D1 DE60037327 D1 DE 60037327D1 DE 60037327 T DE60037327 T DE 60037327T DE 60037327 T DE60037327 T DE 60037327T DE 60037327 D1 DE60037327 D1 DE 60037327D1
Authority
DE
Germany
Prior art keywords
virus
particles
production
new method
improved properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60037327T
Other languages
English (en)
Other versions
DE60037327T2 (de
Inventor
Qinjian Zhao
Shilu Wu
Walter Manger
Shishir Gadam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60037327D1 publication Critical patent/DE60037327D1/de
Publication of DE60037327T2 publication Critical patent/DE60037327T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE2000637327 1999-10-15 2000-10-11 Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften Expired - Lifetime DE60037327T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15981299P 1999-10-15 1999-10-15
US159812P 1999-10-15
PCT/US2000/028064 WO2001028585A1 (en) 1999-10-15 2000-10-11 Novel process for making human papillomavirus virus-like particles with improved properties

Publications (2)

Publication Number Publication Date
DE60037327D1 true DE60037327D1 (de) 2008-01-17
DE60037327T2 DE60037327T2 (de) 2008-11-27

Family

ID=22574151

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000637327 Expired - Lifetime DE60037327T2 (de) 1999-10-15 2000-10-11 Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften

Country Status (8)

Country Link
US (1) US6436402B1 (de)
EP (1) EP1223976B1 (de)
JP (1) JP4689914B2 (de)
AT (1) ATE380034T1 (de)
AU (1) AU772512B2 (de)
CA (1) CA2384844A1 (de)
DE (1) DE60037327T2 (de)
WO (1) WO2001028585A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
MXPA05010285A (es) * 2003-03-24 2005-11-17 Merck & Co Inc Expresion optimizada de hpv 31 l1 en levadura.
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CA2560487C (en) 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
EP1736538A1 (de) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
FR2887457B1 (fr) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Vaccination par ciblage transcutane
ES2423663T3 (es) 2005-08-08 2013-09-23 Oregon Health And Science University Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas
MY162658A (en) * 2007-11-23 2017-06-30 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
CN118059224B (zh) * 2024-02-23 2024-12-24 北京康乐卫士生物技术股份有限公司 九价人乳头瘤病毒疫苗制剂及其应用
WO2025176145A1 (zh) * 2024-02-23 2025-08-28 北京康乐卫士生物技术股份有限公司 九价人乳头瘤病毒疫苗及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US5922588A (en) 1996-10-04 1999-07-13 Merck & Co., Inc. Synthetic HPV16 virus-like particles
ES2268787T3 (es) * 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
CA2355680A1 (en) 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen

Also Published As

Publication number Publication date
JP2003512031A (ja) 2003-04-02
WO2001028585A1 (en) 2001-04-26
CA2384844A1 (en) 2001-04-26
AU8009800A (en) 2001-04-30
US6436402B1 (en) 2002-08-20
JP4689914B2 (ja) 2011-06-01
EP1223976A4 (de) 2004-08-18
EP1223976B1 (de) 2007-12-05
AU772512B2 (en) 2004-04-29
DE60037327T2 (de) 2008-11-27
EP1223976A1 (de) 2002-07-24
ATE380034T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
DE60037327D1 (de) Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
HUP0203056A1 (hu) Vakcinakészítmény
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
JP2003526362A5 (de)
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
CO5280045A1 (es) Nueva composicion
DE122007000090I1 (de) Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
EP1030547A4 (de) Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen
DE69104380D1 (de) Vom genom des papillomavirus-hpv-39 abgeleitete dns-sequenzen, deren anwendung in der in vitro-diagnose und zur herstellung einer immunogenenzusammensetzung.
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
ATE285250T1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
ATE474596T1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
ATE426803T1 (de) In-vitro-methode zur zerlegung und zum wiederzusammenfugen von papillomavirusartigen partikeln
DE60124725D1 (de) Herstellung eines chimeren papillomavirus
MX2024002144A (es) Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
TW200612983A (en) Vaccine
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
JP2001106620A5 (de)

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU

R081 Change of applicant/patentee

Ref document number: 1223976

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1223976

Country of ref document: EP

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20121213